Welcome to our dedicated page for Wuxi Apptec news (Ticker: WUXAY), a resource for investors and traders seeking the latest updates and insights on Wuxi Apptec stock.
WuXi AppTec Co., Ltd. reports developments tied to its global CRDMO platform for pharmaceutical and life sciences customers. The company provides integrated research, development, and manufacturing services across Asia, Europe, and North America, with news commonly focused on operating results, continuing-operations revenue, backlog, guidance, and demand for enabling services.
Recurring updates also cover shareholder-return actions such as cash dividends, A-share repurchases and cancellations, and H-share award trust activity. Other company news includes sustainability disclosures, FTSE4Good Index inclusion, Science Based Targets initiative validation, and site-level developments such as the Nantong facility within its chemistry, biology, and testing service network.
WuXi AppTec has successfully completed its acquisition of OXGENE, a UK-based contract research organization specializing in gene therapy technologies. This acquisition enhances WuXi AppTec's capabilities in offering comprehensive support for cell and gene therapy development. OXGENE will operate as a wholly-owned subsidiary under WuXi Advanced Therapies and will be WuXi ATU's first facility in Europe, allowing for accelerated service offerings and reduced costs in viral vector manufacturing. The strategic move aims to improve accessibility and effectiveness of advanced therapies globally.